INTRODUCTION {#s1}
============

Lung cancer is the leading cause of cancer-related death worldwide \[[@R1]\]. First-line therapy comprises platinum-based chemotherapy and is subsequently followed by second-line cytotoxic chemotherapy. This strategy leads to median progression-free survival of approximately 1 year \[[@R2], [@R3]\]. Activating mutations of the *EGFR* gene are found in a subset of lung carcinomas (10% of adenocarcinomas in the Caucasian population) and define a subpopulation of cancers that can benefit from oral EGFR tyrosine kinase inhibitors (TKIs) \[[@R4]\]. Randomized phase III clinical trials have demonstrated that targeting *EGFR* mutations with these EGFR TKIs as the first-line treatment improves progression-free survival (PFS) and overall survival compared with chemotherapy \[[@R5]-[@R9]\]. Accumulating evidence demonstrates that in addition to *EGFR* mutations, other mutations such as *echinoderm microtubule-associated protein-like 4* (*EML4*) gene fusion to the *anaplastic lymphoma kinase* (*ALK*) gene, or *c-Met* gene amplification or *ROS1* gene rearranged or *ERBB2* exon 20 mutations could be targeted by dedicated targeted therapy with meaningful clinical efficacy \[[@R10]-[@R12]\]. While the above shows that knowledge of tumor genetic profiles is now extremely important to inform treatment decisions, the increasing number of targetable genes raises the problem of detecting mutations using a simple and fast dedicated genetic test.

NGS (Next Generation Sequencing) analysis of tumor cell DNA was developed for this purpose. It has provided physicians with a genomic map of cancer cells and could ease the access to targeted therapy, especially in NSCLC (non-small-cell lung cancer). In this report, we present the experience of our center, where 50 patients with NSCLC underwent NGS analysis. The results were discussed by the Molecular Tumor Board (MTB) to interpret genetic alterations and guide treatment.

PATIENTS AND METHODS {#s2}
====================

Tumor preparation and DNA extraction {#s2_1}
------------------------------------

Fifty formalin-fixed paraffin-embedded tumors from patients treated at the Centre Georges-François Leclerc between May 2012 and October 2014 were characterized by a pathologist to determine the tumor cell content and sent to the molecular biology platform for DNA extraction. Pathological slides were reviewed with the local pathologist for all patients. Blue alcian staining and immunohistochemistry were used to test the expression of p63 and TTF1 for each patient. All samples harbored a tumor cell content superior to 30%, avoiding microdissection experiments. Seven 15μm tumor slices were extracted using the Maxwell 16 FFPE Plus LEV DNA purification kit (Promega, Madison, USA) according to the manufacturer\'s instructions. DNA quality was assessed by spectrophotometry with absorbance at 230, 260, and 280 nm. DNA was quantified using a fluorimetric assay with a Qubit device.

The DNA quantity range was from 500 ng to 1.5 μg, and the DNA quality (260/280) was superior to 1.6 for 48 analyzed samples. For 2 samples, DNA quantity was inferior to 150 ng, and the 260/280 ratio was inferior to 1.2.

Library preparation and sequencing {#s2_2}
----------------------------------

Libraries were prepared with the Truseq Custom Amplicon kit (Illumina, San Diego, USA) and sequenced as described previously \[[@R13]\]. For the design, the DNA target size was around 250 bp. Briefly, 500 ng of gDNA in 5 μl water were hybridized with an oligo pool. Then, unbound oligos were removed, and extension-ligation of bound oligos was followed by PCR amplification. PCR products were cleaned and checked for quality using Tapestation analysis (Agilent). The PCR product size had to be around 350bp. Before sequencing, the libraries were normalized thanks to the normalization process of the Truseq Custom Amplicon kit.

Twelve samples were multiplexed for each run thanks to their specific index combination. Libraries were paired-end sequenced with 2\*151bp cycles on a MiSeq device (Illumina).

Bioinformatics, annotations and interpretation of the results {#s2_3}
-------------------------------------------------------------

The obtained sequences were aligned to the human reference genome hg19 (BWA) and variants were annotated by GATK and Variant Studio software (Illumina). A genetic variant was defined by a Q-score above 30 (except for indel mutations). Every variant was checked manually by a molecular biologist with visualization on Golden Helix Genome Browser. Variants with a frequency above 10% with a coverage depth superior to 300X were retained. The mean coverage was not informative due to the amplicon technology, in opposition to capture technologies. The multiplexing of samples was performed to obtain a minimum of 300X of reads per nucleotide studied.

For each variant, public databases and the literature were searched to classify the effect, the function, and potential therapeutic impact. As described in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}, variations were classified as loss of function, decreased activity, gain of function, SNP, or unknown. For the therapeutic impact, variants were classified as targetable when they were associated with FDA-approved drugs, potentially targetable when their location could be associated with a clinical trial or a potential sensitivity to a drug and not targetable when the location and impact were unknown. When 2 targetable mutations were present in a same sample, we recommended treating the alteration with the higher mutation signal, reflecting the majority clone in the tumor.

Validation of observed mutations {#s2_4}
--------------------------------

Mutations observed in NGS, occurring in genes analyzed in routine diagnosis (for solid tumor) were confirmed by allelic discrimination (*KRAS* mutations on codons 12 and 13, *EGFR* mutations on codons 790 and 858), fragment analysis (*EGFR* deletions for exon 19), and Sanger sequencing (*EGFR* mutations not routinely tested, *BRAF* mutations, *KIT* mutations, *PIK3CA* mutations, *ALK* mutations, and *TP53* mutations). We listed the mutations detected by NGS strategy and confirmed them with standard technics ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}).

Routine testing for lung cancer {#s2_5}
-------------------------------

Routine testing was performed in an independent platform for the analysis of *BRAF codon 600*, *KRAS* codons 12 and 13, and *PIK3CA* codons 542 and 545 *by allelic discrimination. EGFR* exons 18 (G719A/C/S), 20 (T790M) and 21 (L858R and L861Q) mutations were analyzed by allelic discrimination, *EGFR* exons 19 and 20 insertion/deletion analysis was performed by fragment analysis. In case of low input DNA, these exons were analyzed by Sanger sequencing. We listed the mutations detected by standard technics in the routine lab ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}).

Organization of the molecular tumor board: from suggestion to conclusion {#s2_6}
------------------------------------------------------------------------

The decision to evaluate a tumor\'s genetic profile was initially requested by the patient\'s consultant oncologist after oral consent. Analysis was done on the paraffin embedded tumor sample used for the diagnosis or on a new dedicated sample if there was no tissue available. The annotation of the detected variants for each gene indicated the exon, nucleotide, impact at the protein level, and frequency of the variation. The impact of the protein variation on protein function was determined by using data obtained from bibliography and public databases. We classified variations into five different classes: unknown, single-nucleotide polymorphism (SNP), decreased activity, loss-of-function, and activating mutation ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Data analyses were then reviewed by an oncologist and two molecular biologists in order to provide a clinical interpretation of the variations detected. The therapeutic proposal was based on data from the literature, from clinical trial articles, case reports and *in vitro* or *in vivo* research (murine models). In cases where the impact of the mutation was unknown, the therapeutic proposal was based on the location of the mutation in the protein and on bioinformatics predictions of structural changes in protein conformation. After this therapeutic proposals were presented to the Molecular Tumor Board (MTB) (Figure [1](#F1){ref-type="fig"}). These proposals could be: i) inclusion in an early clinical trial, ii) use of a targeted therapy in their classical approval or iii) use of an approved drug in a new indication dictated by the molecular variation.

![MTB, from suggestion to conclusion\
Abbreviations: NGS, Next Generation Sequencing; MTB, Molecular Tumor Board; HES, Hematoxilin Eosine Saffron.](oncotarget-07-24860-g001){#F1}

RESULTS {#s3}
=======

Patients\' characteristics {#s3_1}
--------------------------

NGS analysis of tumor cell DNA was performed on 50 consecutive patients with unresectable locally advanced or metastatic NSCLC. The population was balanced for gender since there were 26 women (52%) and 24 men (48%). The most common histological type was adenocarcinoma (82%, *n* = 41), followed by squamous-cell carcinoma (6.0%, *n* = 3), large-cell neuroendocrine carcinoma (4.0%, *n* = 2), undifferentiated carcinoma (4.0%, *n* = 2), papillary adenocarcinoma (2%, *n* = 1) and sarcomatoid carcinoma (2%, *n* = 1). Twenty-nine (58%) patients were smokers or former smokers, 19 (38%) had never smoked and 2 (4%) had an unknown smoker status. There were 6 patients with locally advanced NSCLC and 44 with metastatic tumors. The sample for NGS analysis was obtained using core needle biopsy of the lung tumor for locally advanced tumor. For other patients the sample was obtained from either primary tumor (21 cases) or metastases (liver in 15 cases, lymph nodes in 6 cases and adrenal tumors in 2 cases). The median age at NSCLC diagnosis was 62.7 years. The patients\' clinical characteristics are presented in Table [1](#T1){ref-type="table"}. Before NGS analysis, routine molecular testing recommended by the French National Cancer Institute was performed. All patients were tested for *EGFR*, *KRAS*, *BRAF*, *PIK3CA* and *ERBB2* by allelic discrimination, fragment analysis or Sanger sequencing. *ALK* rearrangement, *cMET* amplification and *ROS1* rearrangement were analyzed by immunohistochemistry and FISH. Among the 50 patients, 24 (*n* = 48%) harbored a variant revealed by routine molecular testing. The most common variant was an *EGFR* mutation found for 13 patients (9 patients with a deletion in exon 19, and 4 patients with an L858R mutation in exon 21. Two patients harbored a concomitant T790M mutation in exon 20). Five other patients had a *KRAS* mutation, two patients had a *BRAF* mutation, and four had *cMET* amplification (without a mutation). When possible, mutation detected by NGS analysis were confirmed by routine technic.

###### patients\' characteristics

  Characteristic                         Treatment-naive patients   Pretreated patients   Total
  -------------------------------------- -------------------------- --------------------- -----------
  Sex, No. (%)                                                                            
   Female                                5 (41.7)                   21 (52.6)             26 (52.0)
   Male                                  7 (58.3)                   17 (47.4)             24 (48.0)
  Age at diagnosis, years                                                                 
   Median                                60.5                       63.3                  62,7
   Range                                 42-78                      20-79                 20-79
  ECOG performance status, No. (%)                                                        
   0                                     4 (33.3)                   4 (10.5)              8 (16.0)
   1                                     3 (25.0)                   19 (50.0)             22 (44.0)
   2                                     5 (41.7)                   13 (34.2)             18 (36.0)
   ≥ 3                                   0 (0.0)                    2 (5.3)               2 (4.0)
  Cigarette smoking history, No. (%)                                                      
   Never smoked                          5 (41.7)                   14 (36.8)             19 (38.0)
   Former or current smoker              7 (58.3)                   22 (57.9)             29 (58.0)
   Unknown                               0 (0.0)                    2 (5.3)               2 (4.0)
  Histology, No. (%)                                                                      
   Adenocarcinoma                        10 (83.3)                  31 (81.6)             41 (82.0)
   Squamous cell carcinoma               0 (0.0)                    3 (7.9)               3 (6.0)
   Other                                 2 (16.7)                   4 (10.5)              6 (12.0)
  Specific mutation before NGS No. (%)                                                    
   EGFR                                  5 (41.7)                   8 (21.1)              13 (26.0)
   KRAS                                  1 (8.3)                    4 (10.5)              5 (10.0)
   BRAF                                  1 (8.3)                    1 (2.6)               2 (4.0)
   Other                                 0 (0.0)                    4 (10.5)              4 (8.0)
   No mutation                           5 (41.7)                   21 (55.3)             26 (52.0)
  Number of lines of treatment                                                            
   Median                                1.5                        2.6                   2.3
   Range                                 1-3                        1-7                   1-7

NGS analysis revealed new molecular variations {#s3_2}
----------------------------------------------

NGS analyses were requested by a consultant oncologist either at diagnosis of the NSCLC, in treatment-naive patients (22%, *n* = 11) as part of an observational study (ALCAPONE study NCT02281214), or after at least one line of treatment (chemotherapy or targeted therapy) (78%, *n* = 39) in order to find a new therapeutic option due to treatment failure and disease progression. Only two analyses could not be performed due to poor DNA quality probably because of the size of the tumor samples (bronchial aspiration) which results in a small amount of cells inducing a low DNA quantity and higher contaminant content. Figure [2](#F2){ref-type="fig"} represents the flow chart and the detail of the NGS results (Figure [2](#F2){ref-type="fig"}).

![Flowchart of NGS analyses for locally advanced unresectable or metastatic non-small-cell lung cancers\
Abbreviations: NGS, Next Generation Sequencing; DNA Desoxyribonucleic Acid.](oncotarget-07-24860-g002){#F2}

Among the 48 tumors analyzed in this cohort, we detected 124 different mutations. There was a median of two molecular variations per patient (range: 1-14 variations). We detected at least one variation in 46 patients. Interestingly, no patients harbored the same variation profile. The genes with the highest mutation rate were *TP53* (26 mutations observed in 26 different patients), *APC* (18 mutations observed in 15 patients); *EGFR* (23 mutations observed in 20 patients) (Figure [3A](#F3){ref-type="fig"}). These mutations could be grouped in main signaling pathways underlining that gene encoding Tyrosine Kinase Domain Receptors were the most frequently mutated genes (Figure [3B](#F3){ref-type="fig"}). We detected six mutations in the *EGFR* gene in unusual locations, not searched in routine testing (Figure [3C](#F3){ref-type="fig"}). Five patients were reported to have somatic STK11 mutations. No clinical phenotype of Peutz-jegher\'s syndrome was detected in these patients and no germline mutation were detected.

![Mutations discovered using NGS panel\
**A.** Number of tumors with mutation, **B.** Distribution of mutations per signaling pathways. **C.** Representation of *EGFR* gene with the localization of EGFR mutation detected with routine testing and EGFR mutation detected with NGS panel.](oncotarget-07-24860-g003){#F3}

Among the 124 molecular variations detected, bibliographic analysis found 34 targetable mutations in 29 patients. These therapeutic proposals were presented at the MTB. Table [2](#T2){ref-type="table"} summarizes the targetable variants with MTB recommendation and outcome.

###### Treatments recommended by the MTB and implemented or not in patients

  Patients   Mutation                                             Specific Mutation                       Treatment recommended in MTB                         Followed treatment /Line of therapy                                  PFS (Months)
  ---------- ---------------------------------------------------- --------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------- -----------------------
  1          AKT activating mutation / KIT activating mutation    L28F / T594I                            mTOR inhibitor or Imatinib                           Standard treatment (chemotherapy Platin-Pemetrexed)/1                
  2          ALK                                                  R1279K                                  Crizotinib                                           **MTB treatment (Crizotinib)/1**                                     **3**
  3          KRAS                                                 G12V                                    Experimental trial with Selumetinib                  Standard treatment (chemotherapy Platin-Pemetrexed-Bevacizumab) /1   
  4          BRAF                                                 G466E                                   Experimental trial (Acsé Vemurafenib)                **MTB treatment (Acsé Vemurafenib)/1**                               **3**
  5          EGFR activating mutation                             UncommonG735S                           TKI EGFR                                             **MTB treatment(Gefitinib)/2**                                       **7Partial response**
  6          EGFR activating mutation                             UncommonL828S                           TKI EGFR                                             **MTB treatment(Afatinib)/2**                                        **3**
  7          EGFR activating mutation                             UncommonR831H                           TKI EGFR                                             **MTB treatment(Afatinib)/2**                                        **5Partial response**
  8          EGFR activating mutation                             ClassicalE746_A750del                   TKI EGFR                                             **MTB treatment(Erlotinib)/1**                                       **5Partial response**
  9          EGFR activating mutation / RB1 loss of function      ClassicalA747_T751del /L694X            TKI EGFR                                             BSC/3                                                                
  10         EGFR activating mutation / STK11 loss of function    ClassicalE746_A750del /Leu201AlafsX64   TKI EGFR or mTOR inhibitor                           Standard treatment (chemotherapy Platin-Pemetrexed)/1                
  11         EGFR                                                 UncommonP699S                           TKI EGFR                                             BSC/3                                                                
  12         MAP2K1                                               P232L                                   MEK inhibitor                                        **MTB treatment(Trametinib)/3**                                      **unevaluable**
  13         STK11 loss of function                               E256X                                   mTOR inhibitor                                       Standard treatment (chemotherapy Docetaxel)/2                        
  14         STK11 loss of function                               L201AfsX6                               mTOR inhibitor                                       Standard treatment (chemotherapy Pemetrexed)/2                       
  15         MAP2K1                                               P232L                                   MEK inhibitor                                        Standard treatment (chemotherapy Platin-Pemetrexed)/1                
  16         KIT activating mutation                              H630Y                                   Imatinib                                             **MTB treatment(Imatinib)/3**                                        **unevaluable**
  17         KRAS activating mutation                             G12C                                    Experimental trial with Selumetinib                  Standard treatment (chemotherapy Gemcitabine)/3                      
  18         KRAS activating mutation                             G13C                                    Experimental trial with Selumetinib                  BSC/3                                                                
  19         KRAS activating mutation                             G12A                                    Experimental trial with Selumetinib)                 BSC/2                                                                
  20         PDGFRA activating mutation                           R554S                                   Imatinib                                             **MTB treatment/2**                                                  **5Partial response**
  21         PDGFRA activating mutation                           M642I                                   Imatinib                                             BSC/3                                                                
  22         PDGFRA activating mutation / PTEN loss of function   Y555C /R159K                            Imatinib or Experimental trial with PI3K inhibitor   BSC/3                                                                
  23         PI3K activating mutation                             IVS9+1                                  Experimental trial with PI3K inhibitor               BSC/3                                                                
  24         PI3K activating mutation                             H994Y                                   Experimental trial with PI3K inhibitor               BSC/3                                                                
  25         PTEN loss of function                                K62TfsX34                               Experimental trial with PI3K inhibitor               BSC/3                                                                
  26         PTEN loss of function                                S229X                                   Experimental trial with PI3K inhibitor               BSC/2                                                                
  27         PTEN loss of function                                E201K                                   Experimental trial with PI3K inhibitor               BSC/2                                                                
  28         STK11 loss of function                               G279AfsX8                               mTOR inhibitor                                       Experimental trial with anti PDL1/2                                  
  29         STK11 loss of function / KRAS activating mutation    R333C/G12C                              mTOR inhibitor or clinical trial with Selumetinib    Standard treatment (chemotherapy Platin-Pemetrexed)/1                

Abbreviations : BSC, Best supporting care; TKI, Tyrosine kinase inhibitor

Patients\' follow-up and outcomes {#s3_3}
---------------------------------

The median time between the request for a molecular diagnosis and the presentation of a therapeutic proposal by the MTB was 20 calendar days (range: 10 - 62 calendar days). A dedicate biopsy was required for 21 patients. The mean delay from biopsy to MTB decision was 25 days (range: 15-41 calendar days). Half of patients were studied by the MTB while they were still under therapy so that an alternative plan could be prepared for implementation at the time of progression. Of the 24 patients who were still responding to their previous treatment, 18 showed subsequent disease progression. A proposal was given for 11 patients and three of these initiated the treatment proposed by the MTB.

For the 24 other patients presented, the previous treatment had already failed and a proposal was provided by the MTB in 18 cases and initiated in six patients.

To date, treatment decisions according to the molecular results have been followed in nine patients. For the other patients (*n* = 20), the treatment was not based on the MTB proposal because patients were stable on their previous treatment (*n* = 1), or another classical treatment decision was preferred (because of the cost of molecular targeted therapy, or the patient was not eligible for the clinical trial) (*n* = 7); or because of a quick deterioration in the patient\'s performance status or death (*n* = 12).

Nine patients received treatment according to MTB, 3 in first line, 4 after failure of first line and 2 after failure of second line. Four showed a partial response for at least 4 months. Mean progression-free survival was 4.5 months. Two out of the three patients treated with anti EGFR therapy for rare mutation discovered by NGS (and not detected by classical testing) and one patient with classical EGFR mutation, experienced partial response. A patient treated with imatinib for *PDGFRa* mutation also responded to this targeted therapy.

DISCUSSION {#s4}
==========

In the case of NSCLC, a number of driver alterations like mutations, gene translocations or amplifications that can benefit from targeted therapies, have been discovered in the past ten years \[[@R14]\] \[[@R10]-[@R12], [@R15]-[@R17]\]. As a consequence, the tumor molecular status needs to be known before the first-line therapy because these mutations dictate the use of targeted therapies rather than classical chemotherapies. The accumulation of targetable mutations increases the complexity of the analyses carried out at the diagnosis of metastatic diseases, and delays the beginning of therapy. In addition, dedicated molecular testing currently recommended by the French National Cancer Institute does not capture all targetable mutations. Consequently, it appears logical to propose Next Generation Sequencing for lung cancer patients to search for other genomic alterations that could be targetable. We report our experience in using an NGS strategy that includes discussion of cases by a MTB. This strategy is a resource for clinicians as it helps them to interpret genetic profiles and to implement anticancer recommendations. Here, we used a dedicated panel of genes and could test 41 genes at once. In our study, NGS revealed 133 genomic variants in a total of 50 patients. All of the patients but two had at least one genomic mutation. One of the pitfalls of this strategy is that such NGS panel performed only on tumor cells could not make the difference between germline and somatic mutations. However most genes in this panel are targetable oncogenes for which mutations were essentially somatic.

This strategy has the capacity to detect non-canonical variants that may potentially be actionable, rather than routine molecular testing which only focuses on well-known actionable variants. This was particularly important for the *EGFR* gene, for which we found six actionable variants not detected using routine testing. Classical mutations of the *EGFR* gene include exon 19 deletions of 15-18 pb, which represent more than 50% of *EGFR* mutations, and the exon 21 point mutation at the residue L858R, which represents more than 30% \[[@R18]\]. In addition, routine analysis revealed L861Q and G719 mutations, which confer modest sensitivity to EGFR TKI \[[@R19]-[@R21]\]. In addition to these classical mutations, other rare mutations with various degrees of sensitivity to EGFR TKI have been described \[[@R22]-[@R25]\].

Several trial designs are now incorporating genomic information identified through NGS methods \[[@R26]\]. However, the integration of such technology in a practical, efficient, and value-added manner is not straightforward. Some reports are upcoming for American hospitals involving small and heterogenous population of patients with different cancer location \[[@R27]-[@R31]\]. While many clinical trials on this subject are in progress in European countries, no European hospital has reported their experience with such strategy in a daily clinical practice.

The organization of the MTB requires optimal organisation, mainly for the quick analysis and interpretation of data. In this study, the time between the genetic analysis and MTB meeting was less than 30 days for all patients. Despite recommendations for treatments based on molecular analysis, not all patients received the targeted therapy because it was difficult to enroll them in phase I clinical trials or because they were not eligible for clinical trials (e.g. brain metastasis are frequently an exclusion criterion in clinical trials) or because of the patients\' or their physician\'s preference. The result of this was that only a small proportion of patients received the therapy recommended by the MTB. Among 50 patients, the MTB recommended therapy for 29 patients and only 9 received this therapy. In a similar report from the Dartmouth hospital in Lebanon, only 25% of patients received the treatment recommended by the MTB \[[@R29]\]. In the San Diego Moores Cancer Center, NGS analyses affected the cancer treatment in 35.3% of cases \[[@R30]\]. A team from Vanderbilt University also reported that 17.5% of patients (18 of 103) with tumor genetic profiling received targeted therapy \[[@R30]\]. In the case of lung cancer, Hagemann reported that only 11% of sequenced patients received therapy based on NGS testing \[[@R32]\]. These results are very similar to our results.

In conclusion, using an NGS panel to improve molecular testing is feasible in routine practice and the information obtained was clinically relevant and allowed the MTB to propose a therapeutic change in 18% of cases. Our experience in the use of an MTB is too short to determine the clinical benefit of such an approach, but the accumulated evidence suggests that this strategy will become routine in comprehensive cancer centers. A major issue is the low rate of patients that could be treated following the recommendations of the MTB because they were tested at an advanced stage and only received supportive care rather than targeted therapy. So we believe that such analysis should be performed at the diagnosis of the metastatic disease or just after the recurrence after the first line therapy if patients still have a good performance status. The strategy, however, needs to be standardized and algorithms for medical recommendations must be established. There is also a clear need to develop clinical trials to make sure that the use of target therapies based on genotyping by NGS really improves survival in cancer patients.
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